Vexev, announced the highly successful results of the CANSCAN Trial (NCT06691672), providing evidence that the VxWave ...
The VxWave system’s potential ability to standardize examinations would allow dialysis clinics to better determine subgroups who may be at a disadvantage for vascular access creation, ultimately ...
Vexev and U.S. Renal Care today announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system.
Humacyte (HUMA) announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered ...
Texas' transitional dialysis program led to significant decline in utilization of emergency dialysis
The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional ...
The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically ...
The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional dialysis program piloted ...
The cost of emergency dialysis is estimated to be eight times that of in-center dialysis. A new study reveals that a ...
A transitional dialysis program piloted in Austin, TX lowered the use ofcostly emergency dialysis in uninsured people with kidney failure, and it facilitated permanent dialysis access placement and ...
Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback